Loading...
Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
Secondary hyperparathyroidism (SHPT) is common in patients receiving maintenance hemodialysis and is associated with adverse outcomes. Currently, SHPT is managed by reducing circulating levels of phosphate with oral binders and parathyroid hormone (PTH) with vitamin D analogs and/or the calcimimetic...
Na minha lista:
| Udgivet i: | Int J Nephrol Renovasc Dis |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5804266/ https://ncbi.nlm.nih.gov/pubmed/29440923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S128252 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|